Delhi Journal of Ophthalmology

Vitreous Substitutes

salazopyrin lactation

salazopyrin 3d salazopyrin erfaringer
Shorya Vardhan Azad, Deepankur Mahajan, Sidharth Sain, Amit Jain, Brijesh Takkar, Rajvardhan Azad
Dr.Rajendra Prasad Centre for Ophthalmic & Sciences, AIIMS

Corresponding Author:

Dr. Shorya Vardhan Azad
E-Mail :

Published Online: 25-SEP-2013


Vitreous humour is a gelatinous structure that not only maintains the intra ocular pressure but also plays an important role in nourishment of the eye. The search for an ideal vitreous substitute that is transparent, elastic and biocompatible like the vitreous itself is still on. Over a period of time, various compounds have been used such as balanced salt solution, air, gases, perflourocarbons liquids and silicone oil. This review article looks at various conventional and investigational vitreous substitutes in detail.

Keywords :

Vitreous humour is a gelatinous  structure  that fills the space between the lens and the retina.[1] Until recently functions of  vitreous  apart from its  mechanical and  optical  presence, was not well understood. Now we know that vitreous, not only maintains the intra ocular pressure but also plays an important role in nourishment of the eye.[2] The ideal vitreous substitute should be transparent, elastic and biocompatibile as is the vitreous itself. The use of intraocular vitreous substitute was first reported by Ohm in 1911, when he  introduced air into the vitreous cavity to facilitate reattachment of the retina.[3] Over a period of time, various compounds have been used, and many of them play vital role in vitreo-retinal surgery.

Vitreous substitutes can be divided into
  1. Conventional Vitreous substitutes
    Gases – Air, SF6, C3F8

    Liquids - Balanced salt solution, Perflourocarbon liquids and Silicone oil.
  2. Newer Vitreous substitute
    Semi Flourinated Alkanes

    Silicone Oil/ Semi Flourinated Alkanes combinations
  3. Experimental Vitreous substitutes
    • Polymers
      • Hydrogels
      • Smart hydrogels
      • Thermosetting gels
    • Implants
    • Cell culture
Conventional Vitreous substitute



Mainly used intra operatively during  fluid air exchange facilitating retinal reattachment. It is easily available and inexpensive but intraocular time is only 2-3 days, so cannot be used as long term tamponade.[4]

Expansile Gases

Both SF6 and C3F8 have been used commonly in pneumatic retinopexy and in non expansile concentrations for post operative endotamponade.[5-7] Gases have highest surface tension 70 dynes/cm2 which allows them to maintain good tamponading effect.[8] Depending on the percentage of gas injected its intraocular stay ranges from 6-8 days.[9] It is eventually replaced by aqueous avoiding the need for another surgery. Although gases provide excellent results they can lead to cataract formation, corneal endothelial damage, raised IOP and central retinal artery occlusion.[8,10,11] Patients need to avoid change in altitude as it can lead to sudden gas expansion. Gases cannot be used for long-term tamponade in complicated cases as well as inferior tamponade in case of inferior breaks.[6]


Balanced salt solution

Balanced salt solution (BSS) is the most commonly used vitreous substitute, as irrigating solution to replace intraocular volume lost by vitreous removal intra operatively. It has also been used as vehicle to carry drugs for haemostasis, pupillary dilatation and anti-inflammatory effects.[12] Recently low molecular weight heparin and 5 - Fluorouracil  have been added to infusion fluid to prevent post operative proliferative vitreoretinopathy.[13]

Perfluorocarbon liquid

Perfluorocarbon liquid (PFCL) are fluorinated, synthetic, carbon - containing compounds that are clear, colorless, and odorless. PFCLs are immiscible and have a surface tension of approximately 14 to 16 dynes/cm2 measured against air.[14] Perfluorocarbon liquids are also immiscible with silicone oil. PFCLs have capacity for transporting and releasing both O2 and CO2.[15] Most remarkable property of the perfluorocarbon liquids is the specific gravity, which is higher than that of water. Typically the specific gravity range from 1.7 to 2.03. The intraoperative uses of perfluorocarbon liquids depend on their higher specific gravity, because it enables the fluid to settle posteriorly, opening folds in the retina while displacing subretinal fluid anteriorly through pre-existing retinal breaks. The direct toxicity of PFCLs and  their tendency to induce inflammatory reactions  limit use of PFCL as a long-term tamponade.[16] Commonly used PFCLs are perfluorodecalin (PFD), perfluorohexyloctane (F6H8), perfluoroperhydrophenanthrene and octafluoropropane.

Silicone Oil

Silicone Oil (SO) was proposed as a vitreous substitute in 1958 but was first used for ocular surgery by Cibis in 1962.[17] SO are polymers of polydimethylsiloxane.[18] It is transparent, immiscible with water and has a refractive index of 1.4. The viscosity of silicone oil is expressed in centistokes. Most clinical trials have used 1000 and 5000 centistokes silicone oils.[19] Differences among the two determined by the length of the polymer, greater the length, greater the viscosity. SO is the only substance currently accepted for long-term vitreous replacement.[18] Recent studies suggest SO and C3F8 are preferable for long-term tamponade in complicated detachments, and that SO may have advantages over C3F8 in certain clinical situations such as hypotony.[20] It is preferable to use an SO tamponade if post-operative airplane or high elevation travel is planned, or with difficulties in post-operative positioning in children or adults with physical impairment, which makes it a more versatile replacement than air or gas. The time for the removal of SO  is mostly around 3-6 months when the retina is attached and retinal traction is absent.[21] Anatomic outcomes and visual acuity remain stable from 6 to 24 months, which suggests a potential for longer term use.[20] Complications of SO  are emulsification, corneal decompensation, band keratopathy, cataract and glaucoma.[20]

Newer Vitreous Substitutes

Semi Flourinated Alkanes

PFCL offer  higher specific gravity allowing it to settle posteriorly, opening folds in the retina while displacing subretinal fluid anteriorly through pre-existing retinal breaks.[22] A long-term PFCL can set up quite high pressure on the choroid beneath the retina, so that the blood supply to the capillary system is impaired. The low specific gravity of Semi Flourinated Alkanes (SFA) (compared to PFCLs) is thought to produce less retinal damage.[23] SFAs are physically, chemically and physiologically inert, colorless and laser stable with densities reduced to between 1.1 and 1.7g/cm3. SFAs are soluble in PFCLs, hydrocarbons, and silicone oils and have a  refractive index of 1.3.[24] SFAs’ higher interface tension than silicone oil may bridge larger retinal breaks. They have been seen to be well tolerated in the eye upto 3 months, but main limitations are early emulsification and cataract formation.[24,25]

Silicone Oil/ SFA combinations

Till now, no single agent has fulfilled the criterion for an ideal vitreous substitute. Also, none of the available agents provide adequate inferior tamponade, hence by combining the SO and SFAs, the combination takes advantage of the high viscosity of SO and high specific gravity of the SFAs to produce a vitreous substitute with a good tamponade effect and lesser chance of emulsification.[26] SFA is soluble in SO but the solubility is dependent on the viscosity of SO and molecular weight of SFA. Higher the viscosity of SO and higher the molecular weight of SFA both make it less soluble in each other.[24] The combination of both produce either a homogenous clear solutions (heavy silicone oils) or separated solutions (double fills) depending on the ratio of the two liquids.

Heavy Silicone Oil

Heavy Silicone Oil (HSO) is heavier than water. It is a mixture of  SO and a SFA producing a homogenous solution. Newer HSOs are viscous, stable and better tolerated, resulting in longer time tamponade and lesser emulsification.[27] Commonly used agents are Densiron 68, Oxane HD and HWS 46-3000. Recent studies have shown good anatomical and visual outcomes with no emulsification upto 3 months with these agents.[28-30] HSO works well as a long-term tamponade agent for complex retinal detachments involving inferior proliferative vitreoretinopathy.[31]

Double Fill

Double fill (DF) was originally thought to bring about simultaneous superior and inferior tamponade. Since both SFA and SO are hydrophobic it is possible to produce a single bubble with two layers, one layer providing upper support (SO) and the other providing inferior support (SFA).[32] However, DF may not provide enough superior support, as it produces an ‘‘eggshaped’’ bubble with pure F6H8 inferiorly and a lighter solution of F6H8 dissolved in silicone oil superiorly; the bubble as a whole behaves as a tamponade that is heavier than water.[27]

Experimental vitreous substitutes


Focus of recent vitreous substitute research has  been on polymeric hydrogels. Hydrogels are hydrophilic polymers   that form a gel network when crosslinked and are capable of absorbing several times their weight in water and swell.[33] The result is typically a clear viscoelastic gel that strongly resembles the natural vitreous humor. Hydrogels are more favorable vitreous substitutes because they are clear, tend to be biocompatible and can act as a viscoelastic dampener, much like the natural vitreous. Since hydrogels enable diffusion of ions or small particles, they are also currently used as drug  delivery devices in the eye.[34] Their diffusion properties will allow oxygen, nutrients and growth factors to be either implanted in the hydrogel or to pass through from other parts of the eye. The main problem with preformed polymeric hydrogels as vitreous substitutes is that they shear thin upon injection into the eye and lose their elasticity and become more fluid like.[35]

In contrast to injecting a preformed hydrogel that would cause the gel to shear and lose elasticity, hydrogels are injected in aqueous form and then transformed into a gel in situ using a disulfide crosslinker that would retain structure and swell in the eye. Polyvinyl alcohol - methacrylate (PVA-MA) is one such hydrogel which is injected in aqueous form, containing a photoinitiator that can form a hydrogel in situ when irradiated with the proper wavelength of UV radiation.[36] Others like copolyacrylamide gel are first made soluble by reducing disulfide cross-linked bridges and then soluble gel can then be injected which undergoes gelation in situ upon exposure to oxidation by air.[37]

A relatively newer hydrogel, known as smart hydrogel, are stimuli-sensitive and can respond to a variety of signals including pH, temperature, light, pressure, electric fields, or chemicals.[38] These are ionic hydrogels that respond to environmental stimuli  creating a closed feedback loops for drug delivery and other applications. Another experimental agent WTG-127 (Wakamoto Pharmaceutical, Tokyo, Japan) is a type of thermo-setting gel that can gelate at 360C and retains transparency upon gelation.[39]

The main limitation of hydrogels is biocompatibility as it can trigger an immune reaction leading to inflammation and phagocyte mediated disappearance of the gel within weeks of injection.[40] Also, WTG-127 investigators noticed that the gel could drift under a retinal tear.[39] Hence due to early experimental nature of these materials and unknown complications associated with them, they are still at an early experimental stage, but do look promising.


Implantable devices may be able to support the retina and control intraocular pressure without the need of a potentially reactive and biodegradable intravitreally injected solution. Foldable capsular vitreous bodies (FCVB) injected with either saline or silicone oil showed good biocompatibility and retinal support in rabbit eyes over a 180-day implantation time. It is a thin, vitreous-shaped capsule made of a silicone rubber elastomer with a silicone tube valve system filled with a physiologically balanced solution or silicone oil.[41] The silicone rubber capsule has shown good biocompatibility and is easily implanted and removed experimentally in rabbit eyes. Over an 8-week treatment period, there was no corneal opacity, intraocular inflammation, or vitreal opacity but there was a high incidence of cataracts in the rabbit eyes, whether they were caused by the material of the FCVB or the lens structure of their eyes should be further evaluated.

Cell Culture

Recently,  hyalocyte cultures  have developed, which produce hyaluronic acid and other vitreous components.[42]  This could possibily lead to artificial generation of vitreous in vitro, which in turn would solve many problems with artificial substitutes. Vitreous synthesis could be stimulated by hyalocyte proliferation, which has been demonstrated  with ascorbic acid in a dose-dependent manner by increasing collagen production and mRNA expression of cells in vitro.[43] Control of hyalocyte growth can be regulated by specific growth factors  such as bFGF (stimulates) and TGF-ß1( inhibits).[44]


Although various vitreous substitutes are available, there have been issues with the complications that come along with them. Intraocular gases have a risk of elevating intraocular pressure (IOP) and fast intraocular absorption. Conventional substitutes like silicone oil are widely  used, but despite  retinal attachment rate being  80%, it needs to be removed early because of complications like   emulsification, secondary glaucoma and keratopathy. Heavy silicone oil looked promising because of its heavy gravity but unfortunately, it had the weaknesses of significant intraocular inflammatory reactions and caused more severe complications than conventional silicone oil. Polymers  seem to be more biocompatible but they biodegrade quickly.

FCVBs injected with either saline or silicone oil showed good biocompatibility and retinal support but incidence of cataracts was unresolved hence the influence of FCVB on the human lens should be further evaluated. The long-term biocompatibility of these materials needs to be investigated, and to this day there is still a lack of suitable materials to replace the vitreous body.

  1. Sebag J, Balazs EA. Morphology and ultrastructure of human vitreous fibers. Invest Ophthalmol Vis Sci 1989 ;30:1867-71.
  2. Sebag J. Imaging  vitreous. Eye 2002;16:429-39.
  3. Peyman GA, Ericson ES, May DR. A review of substances and techniques of vitreous replacement. Surv Ophthalmol 1972; 17:41-51.
  4. Marcus DM, D’Amico DJ, Mukai S. Pneumatic retinopexy versus scleral buckling for repair of primary rhegmatogenous retinal detachment. Int Ophthalmol Clin 1994; 34:97-108.
  5. Chan CK, Lin SG, Nuthi AS, Salib DM. Pneumatic retinopexy for the repair of retinal detachments: a comprehensive review (1986-2007). Surv Ophthalmol 2008 ;53:443-78.
  6. Chang TS, Pelzek CD, Nguyen RL, Purohit SS, Scott GR, Hay D. Inverted pneumatic retinopexy: a method of treating retinal detachments associated with inferior retinal breaks. Ophthalmology 2003; 110:589-94.
  7. Mansour AM. Inverted pneumatic retinopexy. Ophthalmology 2004; 111(7):1435.
  8. Kim RW, Baumal C. Anterior segment complications related to vitreous substitutes. Ophthalmol Clin North Am 2004; 17():569-76.
  9. Thompson JT. The absorption of mixtures of air and perfluoropropane after pars plana vitrectomy. Arch Ophthalmol 1992; 110:1594-7.
  10. Lee  DA, Wilson  MR, Yoshizumi  MO,  et  al.  The  ocular effects of gases when injected into the anterior chamber of rabbit  eyes. Arch Ophthalmol 1991; 109:571-5.
  11. Wilkinson   C,  Rice   T.   Instrumentation,   materials,   and treatment alternatives,  in  Craven  L (ed) Michels  Retinal Detachment. St. Louis, MO, Mosby, ed 2 1996, pp 391-461.
  12. de Bustros S, Glaser BM, Johnson MA. Thrombin infusion for the control of intraocular bleeding during vitreous surgery. Arch Ophthalmol 1985; 103:837-9.
  13. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, Aylward GW. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy :Results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001; 108:1179-83.
  14. Chang S. Low viscosity liquid fluorochemicals in vitreous surgery. Am J Ophthalmol 1987; 103:38-43.
  15. Peyman  GA, Schulman  JA, Sullivan  B.  Perfluorocarbon liquids in ophthalmology. Surv Ophthalmol  1995; 39:375-95.
  16. Orzalesi  N, Migliavacca L, Bottoni  F, et  al.  Experimental short-term tolerance to perfluorodecalin in the  rabbit  eye: a histopathological study. Curr Eye Res 1998; 17:828-35.
  17. Cibis PA, Becker B, Okun E, Canaan S. The use of liquid silicone in retinal detachment surgery. Arch Ophthalmol 1962; 68:590-9.
  18. Kreiner CF: Chemical and physical aspects of clinically applied silicones. Dev Ophthalmol 1987; 14:11-9.
  19. Foster WJ. Vitreous substitutes. Expert Rev Ophthalmol 2008; 3:211-8.
  20. Azen SP, Scott IU, Flynn HW Jr, et al. Silicone oil in the repair of complex retinal detachments. A prospective observational multicenter study. Ophthalmology 1998; 105:1587-97.
  21. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 1998; 43:3-18.
  22. Ferenc Kuhn, Dante J. Pieramici. Ocular Trauma: Principles and Practice. Page 434.
  23. Matteucci A, Formisano G, Paradisi S, et al. Biocompatibility assessment of liquid artificial vitreous replacements: relevance of in vitro studies. Surv Ophthalmol 2007; 52:289-99.
  24. Meinert H,  Roy T. Semifluorinated alkanes – A new class of compounds with outstanding properties for use in ophthalmology. Eur J  Ophthalmol 2000; 10:189-97.
  25. Kirchhof B, Wong D, Van Meurs J, et al. Use of perfluorohexyloctane as a long-term internal tamponade agent in complicated retinal detachment surgery. Am J Ophthalmol 2002; 133:95-101.
  26. Wetterqvist C, Wong D, Williams R, et al. Tamponade efficiency of perfluorohexyloctane and silicone oil solutions in a model eye chamber. Br J Ophthalmol 2004; 88:692-6.
  27. Heimann H, Stappler T, Wong D. Heavy tamponade 1: a review of indications, use, and complications. Eye 2008; 22:1342-59.
  28. Rizzo S, Genovesi-Ebert F, Belting C, et al. A pilot study on the use of silicone oil-RMN3 as heavier-than-water endotamponade agent. Graefes Arch Clin Exp Ophthalmol 2005; 243:1153-7.
  29. Rizzo S, Genovesi-Ebert F, Vento A, et al. A new heavy silicone oil (HWS 46-3000) used as a prolonged internal tamponade agent in complicated vitreoretinal surgery: a pilot study. Retina 2007; 27:613-20.
  30. Sandner D, Engelmann K. First experiences with highdensity silicone oil (densiron) as an intraocular tamponade in complex retinal detachment. Graefes Arch Clin Exp Ophthalmol 2006; 244:609-19.
  31. Lim BL, Vote B. Densiron intraocular tamponade: a case series. Clin Experiment Ophthalmol 2008; 36:261-4.
  32. Herbert E, Stappler T, Wetterqvist C, et al. Tamponade properties of double-filling with perfluorohexyloctane and silicone oil in a model eye chamber. Graefes Arch Clin Exp Ophthalmol 2004; 242:250-4.
  33. Kopecek J. Polymer chemistry: swell gels. Nature 2002; 417:388-91.
  34. Maruoka S, Matsuura T, Kawasaki K, et al. Biocompatibility of polyvinylalcohol gel as a vitreous substitute. Curr Eye Res 2006; 31:599-606.
  35. Swindle KE, Hamilton PD, Ravi N. In situ formation of hydrogels as vitreous substitutes: viscoelastic comparison to porcine vitreous. J Biomed Mater Res A 2008; 87:656-65.
  36. Cavalieri F, Miano F, D’Antona P, et al. Study of gelling behavior of poly-methacrylate for potential  utilizations in tissue replacement and drug delivery. Biomacromolecules 2004; 5:2439-46.
  37. Swindle-Reilly KE, Shah M, Hamilton PD, et al. Rabbit study of an in situ forming hydrogel vitreous substitute. Invest Ophthalmol Vis Sci 2009; 50:4840-6.
  38. Chaterji S, Kwon IK, Park K. Smart polymeric gels: redefining the limits of biomedical devices. Prog Polym Sci 2007; 32:1083-122.
  39. Katagiri Y, Iwasaki T, Ishikawa T, et al. Application of thermo-setting gel as artificial vitreous. Jpn J Ophthalmol 2005; 49:491-6.
  40. Vijayasekaran S, Chirila TV, Hong Y, et al. Poly(1-vinyl-2-pyrrolidinone) hydrogels as vitreous substitutes: histopathological evaluation in the animal eye. J Biomater Sci PolymEd 1996; 7:685-96.
  41. Gao Q, Mou S, Ge J, et al. A new strategy to replace the natural vitreous by a novel capsular artificial vitreous body with pressure-control valve. Eye 2008; 22:461-8.
  42. Nishitsuka K, Kashiwagi Y, Tojo N, et al. Hyaluronan production regulation from porcine hyalocyte cell line by cytokines. Exp Eye Res 2007; 85:539-45.
  43. Sommer F, Kobuch K, Brandl F, et al. Ascorbic acid modulates proliferation and extracellular matrix accumulation of hyalocytes. Tissue Eng 2007; 13:1281-9.
  44. Sommer F, Pollinger K, Brandl F, et al. Hyalocyte proliferation and ecm accumulation modulated by BFGF and TGF--beta1. Graefes Arch Clin Exp Ophthalmol 2008; 246(9):1275-84.


Azad SV, Mahajan D, Sain S, Jain A, Takkar B, Azad RVitreous Substitutes.DJO 2012;23:9-13


Azad SV, Mahajan D, Sain S, Jain A, Takkar B, Azad RVitreous Substitutes.DJO [serial online] 2012[cited 2019 May 22];23:9-13. Available from: